These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 1764869)

  • 41. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of famotidine on ciprofloxacin pharmacokinetics after single intravenous and oral doses in rats.
    al-Khamis KI; Jim LK; Bawazir SA; Ashour LF; el-Sayed N; el-Sayed YM
    J Clin Pharm Ther; 1994 Dec; 19(6):335-9. PubMed ID: 7876363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers.
    Gao S; Liu GL; Wang SX; Gao XH
    Zhongguo Yao Li Xue Bao; 1991 May; 12(3):195-8. PubMed ID: 1781278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of famotidine in infants.
    Wenning LA; Murphy MG; James LP; Blumer JL; Marshall JD; Baier J; Scheimann AO; Panebianco DL; Zhong L; Eisenhandler R; Yeh KC; Kearns GL
    Clin Pharmacokinet; 2005; 44(4):395-406. PubMed ID: 15828852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal excretion of famotidine and role of adenosine in renal failure induced by bacterial lipopolysaccharide in rats.
    Hasegawa T; Nadai M; Wang L; Takayama Y; Kato K; Nabeshima T; Kato N
    Drug Metab Dispos; 1994; 22(1):8-13. PubMed ID: 8149895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
    Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
    J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics of cimetidine.
    Somogyi A; Gugler R
    Clin Pharmacokinet; 1983; 8(6):463-95. PubMed ID: 6418428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
    Nagita A; Manago M; Aoki S; Mino M; Suzuki K; Ashida K
    Ther Drug Monit; 1994 Oct; 16(5):444-9. PubMed ID: 7846741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.
    Gladziwa U; Klotz U
    Clin Pharmacokinet; 1993 Apr; 24(4):319-32. PubMed ID: 8098275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.
    Duchin KL; McKinstry DN; Cohen AI; Migdalof BH
    Clin Pharmacokinet; 1988 Apr; 14(4):241-59. PubMed ID: 3292102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine.
    Dowling TC; Frye RF; Fraley DS; Matzke GR
    Kidney Int; 2001 Jan; 59(1):295-303. PubMed ID: 11135083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative effects of H2-receptor antagonists on drug interaction in rats.
    Lin JH; Cocchetto DM; Yeh KC; Duggan DE
    Drug Metab Dispos; 1986; 14(6):649-53. PubMed ID: 2877821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T; Hirata W; Higichi S
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Removal of famotidine by haemodialysis in elderly anuric patients.
    Inotsume N; Nishimura M; Nakano M; Fujiyama S; Sagara K; Sato T; Matsushita K; Imai Y; Matsui H
    Eur J Clin Pharmacol; 1990; 38(3):313-4. PubMed ID: 2340853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
    Gladziwa U; Wagner S; Dakshinamurty KV; el Desoky E; Dreuw B; Klotz U
    Eur J Clin Pharmacol; 1993; 44(4):357-60. PubMed ID: 8513846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
    Morgan MY; Stambuk D; Cottrell J; Mann SG
    Aliment Pharmacol Ther; 1990 Feb; 4(1):83-96. PubMed ID: 2104076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Principles of drug administration in renal insufficiency.
    Lam YW; Banerji S; Hatfield C; Talbert RL
    Clin Pharmacokinet; 1997 Jan; 32(1):30-57. PubMed ID: 9012555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.